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In the last decades, many large randomized controlled trials have been conducted to assess the
efficacy and safety of new interventions for the treatment of diabetic kidney disease (DKD).
Unfortunately, these trials failed to demonstrate additional kidney or cardiovascular protection.
One of the explanations for the failure of these trials appears to be the large variation in drug
response between individual patients. All trials to date tested a drug which was targeted to a
large heterogeneous population assuming that every individual will show a similar beneficial
respond to the drug. Post hoc analyses from the past clinical trials, however, suggest that indi-
vidual patients show a marked variation in drug response. This highlights the need to personalize
treatment taking proper account of the characteristics and preferences of individual patients.
Transitioning to a personalized therapy approach will have implications for clinical trial designs,
drug registration and its use in clinical practice. Successful implementation of personalized medi-
cine thus requires engagement of multiple stakeholders including academic community, pharma-
ceutical industry, regulatory agencies, health policy makers, physicians and patients. This
supplement of Diabetes Obesity and Metabolism provides a summary on the state-of-the-art of
personalized medicine in diabetic kidney disease from the views of various stakeholders.
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The prevalence of type 2 diabetes is continuously increasing. Patients
with type 2 diabetes face a high risk of progressive renal function loss
and cardiovascular (CV) disease. The current guideline recommended
treatments target multiple risk factors like glucose, blood pressure,
cholesterol, body weight, smoking, albuminuria in order to reduce the
risk of renal and CV complications. Intervention in the renin-angioten-
sin-aldosterone-system renin-angiotensin_aldosterone-system (RAAS)
with drugs that inhibited the angiotensin-receptor blockade (ARB)
advanced pharmacotherapy in patients with type 2 diabetes and
chronic kidney disease. The RENAAL and IDNT trials showed that
losartan and irbesartan, respectively, reduced renal risk in this popula-
tion.1,2 However, despite the success, the residual risk remains high.
Since the introduction of ARBs for renal protection, many
attempts have been made to further lower renal and CV morbidity by
either more stringently inhibiting the RAAS using dual RAAS blockade
(angiotensin converting enzyme inhibitors [ACEi] + ARB in the VA
NEPHRON-D trial or ARB + direct renin inhibition in the ALTITUDE
trial),3,4 or targeting new risk markers like albuminuria (sulodexide in
the SUN trial),5 hemoglobin (erythropoietin stimulation agent in the
TREAT trial), endothelin-1 (endothelin receptor antagonist in the
ASCEND and SONAR trials)6,7 or inflammation and oxidative stress
(bardoxolone, in the BEACON trial).8 Unfortunately, all these strate-
gies did not result in further renal or CV protection, and sometimes
even resulted in increased risk.
The failure of these trials can be attributed to multiple factors.
Two important factors are, first, a between patient variability in reduc-
tion of the intermediate risk factors (eg, variation in the degree in
blood pressure or albuminuria responses between patients). Second, it
appears that all drugs induced changes in other renal or CV risk
markers (eg, rise in serum potassium and or rise in sodium retention).
Indeed, post hoc analyses of recent trials showed a large variation
in the individual response in the targeted risk marker. For example, in
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the ALTITUDE trial, a large variation in the albuminuria response to
aliskiren was observed (interquartile range −49% to +42%).9 Patients
with a more than 30% reduction in albuminuria were at a 50% lower
risk compared to placebo-treated patients in whom albuminuria did
not change. This suggests that if the clinical trial population was
selected more carefully before starting the trial by selecting only those
individuals with a reduction in albuminuria the outcome of the trial
may have been completely different. Another example comes from
the BEACON trial. The BEACON trial tested the efficacy of the anti-
oxidant anti-inflammatory agent bardoxolone methyl. The trial was
terminated early due to excess heart failure in the bardoxolone methyl
treatment arm most likely due to sodium/fluid retention induced by
the drug.8 A post-hoc analysis of the trial indicated that if patients
would have been selected who are not sensitive for the sodium
retaining effects of the drug, the increased risk for heart failure that
was associated with bardoxolone therapy might have been avoided.10
This would have led to the possibility to characterize the effect of the
drug on renal outcomes more precisely and may have resulted in a
positive outcome of the trial.
The lesson learned from these past trials and their post-hoc ana-
lyses is that we should select clinical trial participants more carefully
with particular emphasis on the individual variability in the drug
response of several risk factors to the new intervention: patients with
“bad” responses should be excluded from trials and patients with
“good” responses should be included. This resembles very much cur-
rent clinical practice in which personalized medicine is more and more
practiced aiming to individualize therapy for each patient.
New trials are indeed going into the direction of personalized
medicine. The SONAR trial is one example. The trial uses an active
enrichment design in which all patients are exposed for 6 weeks to
the tested endothelin receptor antagonist atrasentan.7,11 Patients
who had more than 30% albuminuria reduction during the 6 weeks
active enrichment period will be randomly assigned for long-term
treatment to atrasentan or placebo. Patients who showed excess
sodium retention, measured by a gain in body weight or B-type natri-
uretic peptide, to atrasentan exposure are excluded from the trial. This
way the trial population is enriched for patients who are likely benefit.
The enrichment approach applied in SONAR mimics clinical practice
where the response is monitored after drug initiation and in case of
lack of response or side effects the dose of the drug is down-titrated
or discontinued altogether. The SONAR trial was discontinued earlier
due to a lower than anticipated event rate.7,11 The impact of the
enrichment design element on the event rate remains to be seen.
Past clinical trials in diabetic kidney disease has shown that an
increased attention how individual patients respond to drugs is
needed to improve pharmacotherapy and outcomes of patients. To
personalize pharmacotherapy, drug development and drug use in clini-
cal practice for diabetes kidney disease should be an integrated under-
taking of healthcare providers, the academic community, the
pharmaceutical industry, trial designers, health policy makers, regula-
tory authorities, insurance companies, doctors, patients and the gen-
eral public. Early engagement of these stakeholders is important as
they may have different priorities. A conference on personalized med-
icine in diabetic kidney disease was held in December 2017 in Gro-
ningen, the Netherlands to discuss the state of the art, challenges and
solutions for successful implementation of personalized medicine in
diabetic kidney disease. This supplement of Diabetes Obesity and
Metabolism provides a summary of what was discussed.
A large number of novel biomarkers for diabetic kidney disease
emerged in the past decade. These biomarkers typically address one
specific mechanisms of disease such as inflammation, fibrosis or endo-
thelial function. Since diabetic kidney disease is a heterogeneous dis-
ease biomarker combination which represents different molecular
processes implicated in the progression of diabetic kidney disease
(DKD) may be particularly useful to better phenotype individual
patients and response to interventions in the future. Mulder
et al describe in this supplement of Diabetes Obesity and Metabolism
how systems biology approaches and bio-informatic tools can be used
to achieve this goal.12
A substantial proportion of patients do not respond to guideline
recommended therapies or new therapies. Enriching clinical trials for
patients who respond to the investigational drug, as done in the
SONAR trial, directly raises the question what alternative strategies
are available for non-responder patients. New trial designs methodol-
ogies, like platform design may be a next step to advance enrichment
designs and offer alternative interventions for non-responsive
patients. As described by Heerspink et al in this supplement, platform
designs support the simultaneous conduct of multiple trials in several
related diseases with different interventions using the same infrastruc-
ture.13 Within a platform non-responder patients can theoretically
move on to a new intervention depending whether they responded to
the assigned therapy. The statistical elements for such design require
additional consideration but the platform clearly offers an opportunity
to define an optimal trial population for each new drug.
Implementation of precision medicine involves support from many
stakeholders including regulators, patients, physicians and patients. For
example, regulatory agencies should develop models to assess efficacy
and safety and market drugs for specific targeted patient populations
and healthcare provides/physicians have to develop new guidelines
and implement precision medicine in clinical practice. Most importantly,
patients and patient organizations have to be involved as they are the
end-users and should ultimately benefit from an individualized therapy
approach. The perspectives of these stakeholders are described in the
articles by Mol et al and De Vries et al in this issue.14,15
The treatment of diabetes and diabetic kidney disease as well as
many other chronic diseases has been characterized by a one size fits
all approach. However, recent experiences have taught us that this
approach is no longer sustainable. Examples from the oncology area
where personalized medicine has driven progress for years illustrate
that it is time to change current model of drug development and drug
use in clinical practice. Thus, we are up for a change from “one drug
fits all” into the new era of “a fit for each size.”
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